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Background
Despite development in Anti Retroviral Therapy (ART),
reports of HIV infection remains in continuous momen-
tum and a cure seems to be imaginary. Raltegravir, an
Integrase (IN) inhibitor, provides some life expectancy
to patients on salvage therapy. Nowadays, IN inhibitors
reported with resistance and shows cross resistance to
other drugs in this class. Human Lens Epithelium
Derived Growth Factor (LEDGF)/p75 plays a vital role
in the HIV life cycle and its importance has been shown
in numerous studies. In the LEDGF/p75 IN complex,
LEDGF binds to IN at a region other than the catalytic
active site. Thus, we tried computationally to approach
these IN-LEDGF interaction sites as a novel target in
therapy.
Methods
The computational studies involved protein preparation,
ligand preparation and energy minimization, grid gen-
eration, docking and analysis of results. A library of 396
molecules were prepared considering a pyrimidine ring
as core. These operations were performed using Maes-
tro, Discovery studio and VLife Sciences suites.
Results
It is known that Ile365 establishes a hydrogen bond
with backbone carbonyl group of IN Gln168 whereas
Asp366 of LEDGF/p75 forms a hydrogen bond with
Glu170, on similar basis it was found that AMP_1071
exhibits hydrogen bonding with Gln95 of one mono-
mer and Gln168, Hie171, and Thr174 of another
monomer of IN.
Conclusion
The designed molecule AMP_1071 shows topological
similarity to LEDGF/p75 binding surface. Further anti-
viral activity, pharmacokinetic and tolerability studies
are ongoing. The LEDGF binding inhibitors lacks the
cross resistance to any class of ART, possibly making
this class as add on to highly active anti-retroviral
therapy.
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